Public debate about medicines in the UK is often reduced to a single question: how much do they cost? While price matters, this narrow framing misses the real issue – and makes better decisions harder.

We coined this group 'frontlog', standing in contrast to the 'backlog' narrative that had previously dominated public discourse.